<p>GoodRx Holdings, Inc.（NASDAQ:GDRX - 获取免费报告）的股票在覆盖该股票的十三位分析师中获得了 “持有” 的平均评级，MarketBeat Ratings 报告称。一位研究分析师给予该股票卖出建议，六位分析师给予持有建议，六位分析师给予买入建议。在过去一年中，发布报告的经纪人对该股票的平均一年目标价为 $5.5227。</p>
<ul>
<li>Wegovy 与 Zepbound：谁赢得了 GLP-1 药物之战？</li>
</ul>
<p>GDRX 最近成为多份分析师报告的主题。德意志银行 Aktiengesellschaft 在 8 月 11 日的研究报告中重申了 “持有” 评级，并对 GoodRx 的股票设定了 $6.00 的目标价。华尔街 Zen 在 11 月 15 日的研究报告中将 GoodRx 的股票评级从 “买入” 下调至 “持有”。瑞穗证券在 11 月 6 日的报告中将 GoodRx 的目标价从 $5.00 下调至 $4.00，并对该公司设定了 “中性” 评级。TD Cowen 在 11 月 10 日的研究报告中将 GoodRx 的目标价从 $7.00 下调至 $6.00，并对该股票设定了 “买入” 评级。最后，瑞银集团在 11 月 6 日的研究报告中将 GoodRx 的目标价从 $4.25 下调至 $4.00，并对该公司设定了 “中性” 评级。</p>
<p><strong>查看我们最新的 GoodRx 股票报告</strong></p>
<h2>GoodRx 股票下跌 1.5%</h2>
<ul>
<li>这只医疗保健股票因增长 160% 而备受关注</li>
</ul>
<p>NASDAQ:GDRX 的股票在周五以 $2.71 开盘。该公司的市值为 $9.1986 亿，市盈率为 30.11，市盈率/增长比率为 1.41，贝塔值为 1.47。GoodRx 的 12 个月低点为 $2.61，12 个月高点为 $5.81。该公司的 50 日简单移动平均为 $3.50，200 日简单移动平均为 $4.06。该公司的速动比率为 3.11，流动比率为 3.11，债务与股本比率为 0.81。</p>
<p>GoodRx（NASDAQ:GDRX - 获取免费报告）在 11 月 4 日星期二发布了季度财报。该公司报告本季度每股收益为 $0.08，低于市场共识预期的 $0.09，差额为 ($0.01)。GoodRx 的净利润率为 3.97%，股本回报率为 9.73%。该公司本季度的收入为 $1.9603 亿，而分析师预期为 $1.9517 亿。在去年同期，该公司每股收益为 $0.08。该公司的季度收入同比增长 0.4%。分析师预测 GoodRx 本年度每股收益将达到 0.13。</p>
<h2>GoodRx 的内部活动</h2>
<ul>
<li>基因疗法：为什么单次治疗要花费数百万？</li>
</ul>
<p>在其他新闻中，主要股东 Equity Vii L.P. Spectrum 于 10 月 15 日星期三出售了 23,771 股 GoodRx 股票。股票以平均价格 $4.00 出售，总价值为 $95,084.00。该交易已在提交给证券交易委员会的文件中披露，文件可在此链接查看。公司内部人士目前持有 4.53% 的股票。</p>
<h2>机构投资者对 GoodRx 的看法</h2>
<p>几家对冲基金和其他机构投资者最近买卖了该股票的股份。Quarry LP 在第三季度购买了 GoodRx 的新头寸，价值约 $33,000。Boothbay Fund Management LLC 在第三季度收购了 GoodRx 的新头寸，价值约 $43,000。Citizens Financial Group Inc. RI 在第一季度购买了 GoodRx 的新头寸，价值约 $44,000。Shay Capital LLC 在第三季度收购了 GoodRx 的新股份，价值约 $47,000。最后，Jump Financial LLC 在第一季度收购了 GoodRx 的新股份，价值约 $49,000。63.77% 的股票由机构投资者持有。</p>
<h2>关于 GoodRx</h2>
<p>（获取免费报告）</p>
<p>GoodRx Holdings, Inc. 及其子公司提供信息和工具，使消费者能够比较价格并节省在美国的处方药购买费用。该公司运营一个价格比较平台，为消费者提供经过筛选的、地理相关的处方定价和访问谈判价格的机会。</p>
<h2>另请参阅</h2>
<ul>
<li>我们更看好的五只股票比 GoodRx 更好</li>
<li>我在哪里可以找到 52 周的高点和低点？</li>
<li>Ulta 的股票可能会迎来反弹——20% 的上涨空间？</li>
<li>什么是成长股及其投资</li>
<li>比尔和梅琳达·盖茨基金会出售 MSFT 股票——投资者应该担心吗？</li>
<li>最活跃的股票：美元交易量与股票交易量</li>
<li>MarketBeat 周度回顾 – 12/1 - 12/5</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0RSWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0RSWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 $1,000 在 GoodRx 吗？</h2>
<p>在考虑 GoodRx 之前，你需要听听这个。</p>
<p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 GoodRx 并不在名单上。</p>
<p>虽然 GoodRx 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

GDRX

<p>GoodRx Holdings, Inc.（纳斯达克代码：GDRX）获得了十三位分析师的共识 “持有” 评级。该股票的推荐意见不一：一个 “卖出”，六个 “持有”，六个 “买入”。平均一年目标价格为 5.5227 美元。最近的分析师行动包括德意志银行的 “持有” 评级，目标价为 6 美元，以及瑞银的 “中性” 评级，目标价为 4 美元。GoodRx 的股票开盘价为 2.71 美元，市值为 9.1986 亿美元。机构投资者持有该股票的 63.77%</p>

<p>Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) have been given an average rating of &#34;Hold&#34; by the thirteen analysts that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, six have given a hold recommendation and six have given a buy recommendation to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $5.5227.</p>
<div class="lb-trans"><p>GoodRx Holdings, Inc.（NASDAQ:GDRX - 获取免费报告）的股票在覆盖该股票的十三位分析师中获得了 “持有” 的平均评级，MarketBeat Ratings 报告称。一位研究分析师给予该股票卖出建议，六位分析师给予持有建议，六位分析师给予买入建议。在过去一年中，发布报告的经纪人对该股票的平均一年目标价为 $5.5227。</p>
</div><ul>
<li>Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?</li>
</ul>
<div class="lb-trans"><ul>
<li>Wegovy 与 Zepbound：谁赢得了 GLP-1 药物之战？</li>
</ul>
</div><p>GDRX has been the topic of a number of recent analyst reports. Deutsche Bank Aktiengesellschaft restated a &#34;hold&#34; rating and issued a $6.00 price target on shares of GoodRx in a research report on Monday, August 11th. Wall Street Zen cut shares of GoodRx from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research report on Saturday, November 15th. Mizuho decreased their price target on GoodRx from $5.00 to $4.00 and set a &#34;neutral&#34; rating for the company in a report on Thursday, November 6th. TD Cowen dropped their price objective on GoodRx from $7.00 to $6.00 and set a &#34;buy&#34; rating on the stock in a research note on Monday, November 10th. Finally, UBS Group decreased their target price on GoodRx from $4.25 to $4.00 and set a &#34;neutral&#34; rating for the company in a research note on Thursday, November 6th.</p>
<div class="lb-trans"><p>GDRX 最近成为多份分析师报告的主题。德意志银行 Aktiengesellschaft 在 8 月 11 日的研究报告中重申了 “持有” 评级，并对 GoodRx 的股票设定了 $6.00 的目标价。华尔街 Zen 在 11 月 15 日的研究报告中将 GoodRx 的股票评级从 “买入” 下调至 “持有”。瑞穗证券在 11 月 6 日的报告中将 GoodRx 的目标价从 $5.00 下调至 $4.00，并对该公司设定了 “中性” 评级。TD Cowen 在 11 月 10 日的研究报告中将 GoodRx 的目标价从 $7.00 下调至 $6.00，并对该股票设定了 “买入” 评级。最后，瑞银集团在 11 月 6 日的研究报告中将 GoodRx 的目标价从 $4.25 下调至 $4.00，并对该公司设定了 “中性” 评级。</p>
</div><p><strong>Check Out Our Latest Stock Report on GoodRx</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 GoodRx 股票报告</strong></p>
</div><h2>GoodRx Stock Down 1.5%</h2>
<div class="lb-trans"><h2>GoodRx 股票下跌 1.5%</h2>
</div><ul>
<li>This healthcare stock making a buzz with 160% growth</li>
</ul>
<div class="lb-trans"><ul>
<li>这只医疗保健股票因增长 160% 而备受关注</li>
</ul>
</div><p>Shares of NASDAQ:GDRX opened at $2.71 on Friday. The firm has a market cap of $919.86 million, a P/E ratio of 30.11, a P/E/G ratio of 1.41 and a beta of 1.47. GoodRx has a 12-month low of $2.61 and a 12-month high of $5.81. The business has a fifty day simple moving average of $3.50 and a 200 day simple moving average of $4.06. The company has a quick ratio of 3.11, a current ratio of 3.11 and a debt-to-equity ratio of 0.81.</p>
<div class="lb-trans"><p>NASDAQ:GDRX 的股票在周五以 $2.71 开盘。该公司的市值为 $9.1986 亿，市盈率为 30.11，市盈率/增长比率为 1.41，贝塔值为 1.47。GoodRx 的 12 个月低点为 $2.61，12 个月高点为 $5.81。该公司的 50 日简单移动平均为 $3.50，200 日简单移动平均为 $4.06。该公司的速动比率为 3.11，流动比率为 3.11，债务与股本比率为 0.81。</p>
</div><p>GoodRx (NASDAQ:GDRX - Get Free Report) last issued its quarterly earnings results on Tuesday, November 4th. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.01). GoodRx had a net margin of 3.97% and a return on equity of 9.73%. The company had revenue of $196.03 million during the quarter, compared to analyst estimates of $195.17 million. During the same period in the previous year, the company posted $0.08 EPS. The company's quarterly revenue was up .4% on a year-over-year basis. Analysts predict that GoodRx will post 0.13 earnings per share for the current year.</p>
<div class="lb-trans"><p>GoodRx（NASDAQ:GDRX - 获取免费报告）在 11 月 4 日星期二发布了季度财报。该公司报告本季度每股收益为 $0.08，低于市场共识预期的 $0.09，差额为 ($0.01)。GoodRx 的净利润率为 3.97%，股本回报率为 9.73%。该公司本季度的收入为 $1.9603 亿，而分析师预期为 $1.9517 亿。在去年同期，该公司每股收益为 $0.08。该公司的季度收入同比增长 0.4%。分析师预测 GoodRx 本年度每股收益将达到 0.13。</p>
</div><h2>Insider Activity at GoodRx</h2>
<div class="lb-trans"><h2>GoodRx 的内部活动</h2>
</div><ul>
<li>Gene therapy: Why does it cost millions for a single treatment?</li>
</ul>
<div class="lb-trans"><ul>
<li>基因疗法：为什么单次治疗要花费数百万？</li>
</ul>
</div><p>In other news, major shareholder Equity Vii L.P. Spectrum sold 23,771 shares of GoodRx stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $4.00, for a total value of $95,084.00. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this link. 4.53% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在其他新闻中，主要股东 Equity Vii L.P. Spectrum 于 10 月 15 日星期三出售了 23,771 股 GoodRx 股票。股票以平均价格 $4.00 出售，总价值为 $95,084.00。该交易已在提交给证券交易委员会的文件中披露，文件可在此链接查看。公司内部人士目前持有 4.53% 的股票。</p>
</div><h2>Institutional Investors Weigh In On GoodRx</h2>
<div class="lb-trans"><h2>机构投资者对 GoodRx 的看法</h2>
</div><p>Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Quarry LP bought a new position in shares of GoodRx during the 3rd quarter worth about $33,000. Boothbay Fund Management LLC acquired a new position in GoodRx during the 3rd quarter worth approximately $43,000. Citizens Financial Group Inc. RI bought a new position in GoodRx in the first quarter worth approximately $44,000. Shay Capital LLC acquired a new stake in GoodRx in the third quarter valued at approximately $47,000. Finally, Jump Financial LLC acquired a new stake in GoodRx in the first quarter valued at approximately $49,000. 63.77% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>几家对冲基金和其他机构投资者最近买卖了该股票的股份。Quarry LP 在第三季度购买了 GoodRx 的新头寸，价值约 $33,000。Boothbay Fund Management LLC 在第三季度收购了 GoodRx 的新头寸，价值约 $43,000。Citizens Financial Group Inc. RI 在第一季度购买了 GoodRx 的新头寸，价值约 $44,000。Shay Capital LLC 在第三季度收购了 GoodRx 的新股份，价值约 $47,000。最后，Jump Financial LLC 在第一季度收购了 GoodRx 的新股份，价值约 $49,000。63.77% 的股票由机构投资者持有。</p>
</div><h2>About GoodRx</h2>
<div class="lb-trans"><h2>关于 GoodRx</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.</p>
<div class="lb-trans"><p>GoodRx Holdings, Inc. 及其子公司提供信息和工具，使消费者能够比较价格并节省在美国的处方药购买费用。该公司运营一个价格比较平台，为消费者提供经过筛选的、地理相关的处方定价和访问谈判价格的机会。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另请参阅</h2>
</div><ul>
<li>Five stocks we like better than GoodRx</li>
<li>Where Do I Find 52-Week Highs and Lows?</li>
<li>Ulta’s Stock May Be Set for a Glow-Up—20% Upside Ahead?</li>
<li>What Are Growth Stocks and Investing in Them</li>
<li>Gates Foundation Sells MSFT Stock—Should Investors Be Worried?</li>
<li>Most active stocks: Dollar volume vs share volume</li>
<li>MarketBeat Week in Review – 12/1 - 12/5</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 GoodRx 更好</li>
<li>我在哪里可以找到 52 周的高点和低点？</li>
<li>Ulta 的股票可能会迎来反弹——20% 的上涨空间？</li>
<li>什么是成长股及其投资</li>
<li>比尔和梅琳达·盖茨基金会出售 MSFT 股票——投资者应该担心吗？</li>
<li>最活跃的股票：美元交易量与股票交易量</li>
<li>MarketBeat 周度回顾 – 12/1 - 12/5</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0RSWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=GDRX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in GoodRx Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 GoodRx 吗？</h2>
</div><p>Before you consider GoodRx, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 GoodRx 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GoodRx wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 GoodRx 并不在名单上。</p>
</div><p>While GoodRx currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 GoodRx 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

GoodRx Holdings, Inc.（纳斯达克代码：GDRX）被分析师一致评为 “持有”